Scott Ogg
Vice President
Corporate Development and Operations
ARMO Biosciences
Japan
Biography
Scott Ogg, PhD joined ARMO as its Vice President of Corporate Development and Operations in May 2013. Prior to joining ARMO, Scott was Director, Project and Portfolio Management at Gilead (GILD) where he managed oncology and hepatitis programs. Scott was on the start-up team of ARRESTO BioSciences where he played an instrumental role in the acquisition of the company by Gilead and the completion of the Series B and C financings as Senior Director of Project and Alliance Management. Previously, he held positions of increasing responsibility at Exelixis (EXEL) and Nektar Therapeutics (NKTR) where he managed the early development of MOVANTIK™(naloxegol). Scott completed post-doctoral studies at Harvard University Medical School/Massachusetts General Hospital and received a Ph.D. in Cellular & Molecular Physiology from Tufts University Sackler School of Graduate Biomedical Sciences and a B.A. in Biology from Albion College. He is author and inventor on several publications and patents.
Research Interest
Oncology, Business Management
